What the six lenses say about SHILPAMED — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.
How SHILPAMED’s own sector index is moving — context for reading the stock’s six lenses.
Six-lens read
The actual numbers
The actual numbers
Full 8-quarter history in the financials table below.
The actual numbers
The actual numbers
Every filing in the corporate-announcements panel below.
The actual numbers
Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.
Conviction — the average of the two active conviction-lens deciles (Technical & Flow):
Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.
Glass box
Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.
Policy
Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.
PLI Scheme — Pharmaceuticals & API
Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices
Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.
| Baseline | 1D | 1W | 1M | 3M | 6M | 12M |
|---|---|---|---|---|---|---|
Nifty 50 Large-cap anchor | -2.1pp | +0.2pp | +30.6pp | +73.6pp | +184.8pp | +125.6pp |
Nifty 500 Broad-market baseline | -2.1pp | +0.2pp | +29.6pp | +72.0pp | +179.0pp | +120.4pp |
Sector Own-sector index | — | — | +26.7pp | +66.0pp | +165.9pp | +99.6pp |
From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).
Trend
SHILPAMED daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.
Relative strength
SHILPAMED ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.
TradingView composite technical analysis — multi-timeframe consensus
Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.
| Metric | Jun '24 | Sep '24 | Dec '24 | Mar '25 | Jun '25 | Sep '25 | Dec '25 | Mar '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue (₹cr) | 293 | 344 | 319 | 331 | 321 | 370 | 410 | 437 |
| ↳ change QoQ | — | +17.5% | -7.1% | +3.7% | -3.0% | +15.3% | +10.8% | +6.6% |
| EBITDA (₹cr) | 83 | 91 | 82 | 79 | 91 | 108 | 114 | 120 |
| EBITDA margin | 28.4% | 26.5% | 25.6% | 23.9% | 28.3% | 29.2% | 27.8% | 27.5% |
| PAT (₹cr) | 14 | 18 | 32 | 15 | 47 | 44 | 45 | 108 |
| ↳ change QoQ | — | +27.6% | +77.2% | -52.8% | +213.3% | -6.4% | +2.3% | +140.0% |
| Net margin | 4.8% | 5.2% | 10.0% | 4.5% | 14.6% | 11.9% | 11.0% | 24.7% |
| EPS (₹) | 1.46 | 1.83 | 3.25 | 0.74 | 2.40 | 2.25 | 2.28 | 5.51 |
| D/E | — | — | — | — | — | — | — | — |
Filings to the exchange — capital actions, earnings and governance. Most recent first.
A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗An exchange filing — open the original disclosure on NSE for the full text.
View original filing on NSE ↗An exchange filing — open the original disclosure on NSE for the full text.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗An exchange filing — open the original disclosure on NSE for the full text.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗An exchange filing — open the original disclosure on NSE for the full text.
View original filing on NSE ↗A governance / disclosure filing — lower signal weight, context only.
View original filing on NSE ↗An exchange filing — open the original disclosure on NSE for the full text.
View original filing on NSE ↗…and 5 more.
Ownership
Mutual funds holding SHILPAMED (6)
| Fund | Weight | AUM ₹cr | Grade |
|---|---|---|---|
| Aditya BSL Small Cap Gr | 0.58% | 5,865 | |
| HDFC Pharma and Healthcare Reg Gr | 2.25% | 2,940 | |
| Aditya BSL Pharma & Hlthcare Reg Gr | 2.32% | 1,074 | |
| Bandhan Healthcare Reg Gr | 2.49% | 319 | |
| ITI Pharma and Healthcare Reg Gr | 1.15% | 263 | |
| Samco Small Cap Reg Gr | 0.66% | 170 |
ETFs holding SHILPAMED (0)
No tracked ETF holds SHILPAMED ≥0.5%.